WO1998031806A3 - Fc receptors and polypeptides - Google Patents

Fc receptors and polypeptides Download PDF

Info

Publication number
WO1998031806A3
WO1998031806A3 PCT/US1998/001184 US9801184W WO9831806A3 WO 1998031806 A3 WO1998031806 A3 WO 1998031806A3 US 9801184 W US9801184 W US 9801184W WO 9831806 A3 WO9831806 A3 WO 9831806A3
Authority
WO
WIPO (PCT)
Prior art keywords
fcr
iii
methods
polypeptides
proteins
Prior art date
Application number
PCT/US1998/001184
Other languages
French (fr)
Other versions
WO1998031806A2 (en
WO1998031806A9 (en
Inventor
Henrik S Olsen
Jian Ni
Marianne Murphy
Steven M Ruben
Reiner L Gentz
Original Assignee
Human Genome Sciences Inc
Henrik S Olsen
Jian Ni
Marianne Murphy
Steven M Ruben
Reiner L Gentz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Henrik S Olsen, Jian Ni, Marianne Murphy, Steven M Ruben, Reiner L Gentz filed Critical Human Genome Sciences Inc
Priority to AU59273/98A priority Critical patent/AU5927398A/en
Priority to CA002278154A priority patent/CA2278154A1/en
Priority to JP53469398A priority patent/JP2001509030A/en
Priority to EP98902673A priority patent/EP0972023A2/en
Publication of WO1998031806A2 publication Critical patent/WO1998031806A2/en
Publication of WO1998031806A3 publication Critical patent/WO1998031806A3/en
Publication of WO1998031806A9 publication Critical patent/WO1998031806A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to four novel Fc receptor-like proteins which are members of the Fc Receptor family. In particular, isolated nucleic acid molecules are provided encoding the human FcR-I, FcR-II, FcR-III, and FcR-IV proteins. FcR-I, FcR-II, FcR-III, and FcR-IV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists FcR-I, FcR-II, FcR-III, and FcR-IV activities. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
PCT/US1998/001184 1997-01-21 1998-01-20 Fc RECEPTORS AND POLYPEPTIDES WO1998031806A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU59273/98A AU5927398A (en) 1997-01-21 1998-01-20 Fc receptors and polypeptides
CA002278154A CA2278154A1 (en) 1997-01-21 1998-01-20 Fc receptors and polypeptides
JP53469398A JP2001509030A (en) 1997-01-21 1998-01-20 Fc receptor and polypeptide
EP98902673A EP0972023A2 (en) 1997-01-21 1998-01-20 Fc RECEPTORS AND POLYPEPTIDES

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3420597P 1997-01-21 1997-01-21
US60/034,205 1997-01-21
US4987297P 1997-06-18 1997-06-18
US60/049,872 1997-06-18

Publications (3)

Publication Number Publication Date
WO1998031806A2 WO1998031806A2 (en) 1998-07-23
WO1998031806A3 true WO1998031806A3 (en) 1998-11-12
WO1998031806A9 WO1998031806A9 (en) 1999-01-14

Family

ID=26710690

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/001184 WO1998031806A2 (en) 1997-01-21 1998-01-20 Fc RECEPTORS AND POLYPEPTIDES

Country Status (6)

Country Link
US (2) US20030208054A1 (en)
EP (1) EP0972023A2 (en)
JP (1) JP2001509030A (en)
AU (1) AU5927398A (en)
CA (1) CA2278154A1 (en)
WO (1) WO1998031806A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6384203B1 (en) 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
US6448035B1 (en) 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US20060078564A1 (en) 2002-05-08 2006-04-13 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
MXPA01011274A (en) * 1999-05-07 2002-05-06 Merck Patent Gmbh Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use.
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
AU3300301A (en) * 2000-01-25 2001-08-07 Hyseq Inc Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides
US20040092714A1 (en) * 2000-09-05 2004-05-13 Yongwon Choi Osteoclast-associated receptor
PL374463A1 (en) * 2001-11-14 2005-10-17 Immunex Corporation Modulation of lir function to treat rheumatoid arthritis
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1697520A2 (en) * 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
EP2053062A1 (en) * 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8207110B2 (en) * 2004-09-03 2012-06-26 The Trustees Of Columbia University In The City Of New York ITL3 polypeptides and uses thereof
WO2006031994A2 (en) * 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
WO2006053301A2 (en) 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
WO2006076594A2 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
AU2006302254B2 (en) 2005-10-06 2011-05-26 Xencor, Inc. Optimized anti-CD30 antibodies
RS53263B (en) 2006-08-14 2014-08-29 Xencor Inc. Optimized antibodies that target cd19
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
AU2008209436A1 (en) * 2007-01-23 2008-07-31 Zymogenetics, Inc. Soluble Fc gamma R1a for reducing inflammation
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
SI2808343T1 (en) 2007-12-26 2019-10-30 Xencor Inc Fc variants with altered binding to FcRn
JP2009201403A (en) * 2008-02-27 2009-09-10 Tosoh Corp POLYNUCLEOTIDE ENCODING HUMAN Fc RECEPTOR, AND METHOD FOR PRODUCING HUMAN Fc RECEPTOR UTILIZING THE SAME
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
JP6280499B2 (en) * 2011-07-08 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Purification method of FC fusion protein
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
JP6699085B2 (en) * 2015-03-25 2020-05-27 東ソー株式会社 Method for purifying Fc binding protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198342A (en) * 1990-07-05 1993-03-30 Immunex Corporation DNA encoding IgA Fc receptors

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL SEQUENCES EMBL, Heidelberg, FRG; 12 September 1997 (1997-09-12), ARM J.P. ET AL.: "Human clone HM43 monocyte inhibitory receptor precursor", XP002063720 *
DATABASE EMBL SEQUENCES EMBL, Heidelberg, FRG; 2 December 1997 (1997-12-02), BORGES L. ET AL.: "Homo sapiens leucocyte immunoglobulin-like receptor-4 (LIR-4)", XP002063719 *
DATABASE EMBL SEQUENCES EMBL, Heidelberg, FRG; 5 December 1997 (1997-12-05), SAMARIDIS J. ET AL.: "H. sapiens immunoglobulin-like transcript 6 (ILT-6)", XP002063718 *
HIBBS M.L. ET AL.: "Molecular cloning of a human immunoglobulin G Fc receptor", PROC. NATL. ACAD. SCI. USA, vol. 85, no. 7, April 1988 (1988-04-01), pages 2240 - 2244, XP002063716 *
KATZ H.R. ET AL.: "Mouse mast cell gp49b1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high affinity Fc receptor for IgE", PROC. NATL. ACAD. SCI. USA, vol. 93, October 1996 (1996-10-01), pages 10809 - 10814, XP002063715 *
RAGHAVAN M ET AL: "FC RECEPTORS AND THEIR INTERACTIONS WITH IMMUNOGLOBULINS", ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, vol. 12, 1996, pages 181 - 220, XP000676674 *
SAMARIDIS J. & COLONNA M.: "Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways.", EUR. J. IMMUNOL., vol. 27, no. 3, March 1997 (1997-03-01), pages 660 - 665 *
STENGELIN S. ET AL.: "Isolation of cDNAs for two distinct human Fc receptors by ligand affinity cloning", EMBO JOURNAL, vol. 7, no. 4, April 1988 (1988-04-01), pages 1053 - 1059, XP002063717 *

Also Published As

Publication number Publication date
EP0972023A2 (en) 2000-01-19
WO1998031806A2 (en) 1998-07-23
US20040147733A1 (en) 2004-07-29
JP2001509030A (en) 2001-07-10
US20030208054A1 (en) 2003-11-06
AU5927398A (en) 1998-08-07
CA2278154A1 (en) 1998-07-23

Similar Documents

Publication Publication Date Title
WO1998031806A3 (en) Fc receptors and polypeptides
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
AU9482498A (en) Interleukin-17 receptor-like protein
CA2266439A1 (en) Neutrokine .alpha.
NZ510367A (en) Interleukin 17-like receptor protein nucleic acid sequence encoding the interleukin receptor protein and method of expressing protein in recombinant vector
WO1998031818A3 (en) Tace-like and matrilysin-like polypeptides
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
CA2285040A1 (en) Death domain containing receptor 5
EP1003767A4 (en) Human tumor necrosis factor receptor tr10
WO2000067793A8 (en) Death domain containing receptor 4
WO2002083856A3 (en) Polynucleotides encoding two novel human g-protein coupled receptors, hgprbmy28 and hgprbmy29, and splice variants thereof
WO2004039940A3 (en) Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
WO2000056405A3 (en) Human tumor necrosis factor receptor-like 2
WO2003083078A3 (en) Novel human cell surface protein with immunoglobulin folds, bgs-19
DE69841751D1 (en) Chemokin alpha-5
WO2003027231A3 (en) Polynucleotide encoding adapter protein, pmn29
EP1712631A3 (en) Fc receptors and polypeptides
WO2001032128A3 (en) Human chemokine beta-13
WO2000039136A3 (en) Human brainiac-5
WO2005003299A3 (en) Polynucleotides encoding novel guanylate binding proteins (gbp's)
WO2003083076A3 (en) Polynucleotides encoding novel two splice variants of a human cell surface protein with immunologobulin folds, bgs5g and bgs5i
WO2002018622A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
EP1187842A4 (en) Human tumor necrosis factor receptor tr10
WO2003031566A3 (en) Keratinocyte derived interferon
WO2002046414A3 (en) Human g-protein coupled receptor expressed highly in kidney

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1-101, DESCRIPTION, REPLACED BY NEW PAGES 1-113; PAGES 102-119, CLAIMS, REPLACED BY NEW PAGES114-134; PAGES 1/21-21/21, DRAWINGS, REPLACED BY NEW PAGES 1/21-21/21; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase

Ref document number: 2278154

Country of ref document: CA

Ref country code: CA

Ref document number: 2278154

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 534693

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998902673

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998902673

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998902673

Country of ref document: EP